coyatherapeutics.com
  • About Us
      • Back
      • Story and Approach
      • Management Team
  • Science & Technology
      • Back
      • Treg Overview
      • Manufacturing Overview
      • Exosome Overview
      • Publications
  • Pipeline
      • Back
      • Pipeline
      • Indications
  • News
      • Back
      • News
      • Press Releases
      • Blog
      • Presentations
      • Events
  • Patient Resources
      • Back
      • Clinical Trial Information
  • Contact Us
line

Coya Therapeutics fireside chat with David Sherman at LifeSci Summer Symposium

Houston, TX., -- Coya Therapeutics, Inc., (Coya), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Tregs) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, presented a corporate overview by Howard Berman, Ph.D., Chief Executive Officer of Coya Therapeutics, at the LifeSci Summer Symposium held virtually on July 21, 2021.

LifeSci Summer Symposium
Location:           Webcast Link

Harnessing adoptive
regulatory T cells (Tregs)
to target disease

Contact Us
Gantry 5
© 2022 Coya Therapeutics, Inc. All rights reserved
  • About Us
      • Back
      • Story and Approach
      • Management Team
  • Science & Technology
      • Back
      • Treg Overview
      • Manufacturing Overview
      • Exosome Overview
      • Publications
  • Pipeline
      • Back
      • Pipeline
      • Indications
  • News
      • Back
      • News
      • Press Releases
      • Blog
      • Presentations
      • Events
  • Patient Resources
      • Back
      • Clinical Trial Information
  • Contact Us
Terms of Use  Privacy Policy  

Follow Us

5850 San Felipe St Suite 500
Houston TX 77057
1 (800) 587-8170

Harnessing potent
immunomodulatory T cells (Tregs) and TREG derived
Exosomes to target disease

Contact Us